Group 1 - The event "Investors Walk into Listed Companies" aims to enhance communication between investors and companies, promoting financial knowledge and rational investment [1] - Yuyuan Group, rooted in China, focuses on family happiness consumption, with a diverse portfolio including gold jewelry, cultural dining, liquor, health, and fashion [1] - The company has been optimizing its business layout and expanding overseas markets, aiming to create a global fashion cultural showcase [2] Group 2 - The CFO of Tonghanchuntang emphasized the brand's commitment to traditional Chinese medicine, focusing on innovation and the development of health products [2] - The event included a tour of Yuyuan's gold jewelry store, showcasing various products that blend traditional culture with modern design [3] - Yuyuan Group plans to enhance Tonghanchuntang's brand value by focusing on the food-medicine integration field and expanding distribution channels [4] Group 3 - The company is confident in its long-term development in the gold jewelry sector despite fluctuations in gold prices, implementing strategies to optimize product structure and expand sales channels [3] - The event facilitated a deeper understanding of Yuyuan Group's achievements in the gold and health sectors, strengthening investor relations [4]

海外专家盛赞中医药抗衰老研究 近日，第五届"亚洲医疗健康高峰论坛"在香港举行，吸引了来自40多个国家和地区的2800多名科研人 员、投资者和企业家线上线下（300959）共同参与，探讨全球医疗健康领域的未来发展与合作机遇。香 港特区行政长官李家超、国家卫生健康委员会副主任曹雪涛院士出席高峰论坛并致辞，世界卫生组织总 干事谭德塞发表视频致辞。 在席卷全球的"银发浪潮"背景下，如何科学抗衰老、实现健康老龄化，成为高峰论坛上最炙手可热的前 沿议题之一。世界中医药学会联合会抗衰老专委会秘书长侯云龙教授在论坛上分享的基于中医气络学说 精气神理论的系列研究——八子补肾胶囊在抗衰老方面的探索与实践，引发了与会各国专家的浓厚兴 趣。 中西医结合推动抗衰老研究新突破 "在国内，60岁及以上人口去年底首次超过了3亿，占总人口22%。衰老带来的各种健康问题越来越突 出。"侯云龙教授在报告开篇点明了研究的现实意义。他介绍，中医理论认为"肾为先天之本"，肾精的 盛衰贯穿人的一生。随着年龄增长，肾精消耗，身体机能就会下降，出现体力变差、记性不好、头发变 白、骨头变脆等衰老现象。 基于此，气络学说精气神理论提出，衰老的核心在于"肾精虚衰" ...

私域选品新趋势：从"卖货"到"卖解决方案" 传统私域运营依赖"低价爆款"的单一逻辑，陷入同质化竞争与用户流失困境。如今消费者对健康产品的 需求从"概念营销"转向"实效改善"，私域选品正从单纯'卖货'向'卖解决方案'转型升级—— 兼具功效确 定性、服务延续性、社交传播性的产品，成为破局关键。 "高复购的健康产品必须解决两个核心问题：一是真实可感知的功效，二是持续的服务价值。"沸点会现 场，以岭健康相关负责人指出，"以岭的产品不是简单的中药材叠加，而是以'通络养生八字经'(通络、 养精、动形、静神)为理论指导，结合现代健康需求，形成的中医专利组方产品，针对现代人亚健康痛 点，提供从理论到产品的全链条体系化健康解决方案。" 当"边熬边补"的朋克养生升级为"精准调理"的科学管理，养生消费迈入全新发展阶段。数据显示，当前 我国年轻人群体中，养生青年占比已经高达83.7％，保健养生消费在18 - 35岁年轻人群的消费榜单中强 势崛起，稳稳跻身前三甲。这一代年轻消费者，秉持着"功能性养生零食+即时调理"的全新消费诉求， 正有力推动中医药大健康产品成为消费市场的"新宠儿"。 在此背景下，以岭健康以"通络养生八字经"为核心，打 ...

Core Viewpoint - The modernization of traditional Chinese medicine (TCM) is being driven by technological innovation, aiming to enhance its industrialization and internationalization while preserving its ancient heritage [1][2]. Group 1: Industry Development - Yunnan province possesses over 90% of China's medicinal plant resources, with 25% of the country's major medicinal materials sourced from the region [2]. - The area is projected to reach a medicinal herb planting area of 10.92 million acres by 2024 [2]. - Companies like Yunnan Baiyao and Shenwei Shipuri Pharmaceutical are leveraging modern biotechnology to develop innovative products, filling industry gaps and integrating traditional medicine into modern healthcare [2]. Group 2: Technological Innovation - A comprehensive national survey of medicinal resources has been conducted using advanced technologies, providing a modern scientific basis for TCM theories [3]. - Breakthroughs in various fields such as seed industry, cultivation, drug development, and digital technology are being achieved, transitioning TCM from traditional practices to innovative applications [3]. Group 3: Collaborative Ecosystem - The TCM industry is expected to reach a market size of nearly one trillion yuan by 2025, encompassing various sectors including medicinal materials and proprietary Chinese medicines [4]. - A collaborative innovation system is essential, requiring integration among government, industry, academia, and research to share resources and mitigate risks [4]. - Recommendations include establishing a dynamic monitoring network for medicinal resources and enhancing intellectual property protections to stimulate R&D investments [4]. Group 4: Talent and Policy Support - Yunnan is focused on developing a world-class modern medicinal materials industry, emphasizing research, cultivation, processing, and market development [5]. - The province has optimized its innovation policy environment, providing substantial support for TCM enterprises and attracting high-end talent [6]. - The integration of modern technologies in TCM is expected to significantly contribute to the health initiatives in China [6].

Core Insights - The rise of Traditional Chinese Medicine (TCM) night markets across the country reflects a growing public interest in health management and wellness practices, particularly during the recent May Day holiday where a TCM cultural night market in Shenyang attracted approximately 50,000 visitors in a single day [1] - TCM night markets combine traditional practices such as acupuncture and cupping with modern wellness activities, making TCM more accessible and appealing to the public [1] - The popularity of TCM night markets is supported by government initiatives that integrate medical, cultural, and commercial resources, transforming these markets into large-scale events that enhance their influence and reach [1] Industry Development - TCM night markets provide a practical avenue for the dissemination of TCM culture, enriching residents' nightlife while promoting health awareness [2] - There is a need for the establishment of management systems to ensure safety and standardization in TCM night markets, which can enhance the overall experience for visitors [2] - Efforts should be made to create brand recognition and diversify activities and products within the night markets, particularly targeting younger demographics to foster familiarity and acceptance of TCM [2]

Core Viewpoint - The company, Jiaying Pharmaceutical, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact its operations and reputation [1]. Group 1: Company Overview - Jiaying Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine, holding a significant position in the industry with 58 drug varieties across 5 dosage forms [3]. - The company's leading products, Shuangliao Houfeng San and Zhonggan Ling Pian, have been recognized as national protected traditional Chinese medicine varieties and have won the "Guangdong Province Famous Brand Product" title [3]. - Jiaying Pharmaceutical's subsidiary, Jiaying Hunan, produces unique products listed in the national medical insurance directory, including Jieguzhi Qili Pian and Jieguzhi Qili Jiao Nang, both of which have patent authorization [3]. Group 2: Financial Performance - In 2024, Jiaying Pharmaceutical reported total revenue of 376 million yuan, a year-on-year decline of 29.46%, and a net profit attributable to shareholders of 20.61 million yuan, down 39.94% [3]. - Despite the financial challenges, the company has implemented measures such as optimizing production processes and enhancing cost control to maintain stable core business operations [3]. - In Q1 2025, Jiaying Pharmaceutical achieved revenue of 122 million yuan, a year-on-year increase of 28.83%, primarily due to expanded sales channels [3]. - The net profit attributable to shareholders for the same period was 15.40 million yuan, reflecting a significant year-on-year growth of 197.23%, driven by successful partnerships with major retail chains and improved cost management [3]. Group 3: Corporate Governance - During a recent earnings briefing, the company addressed investor concerns regarding its governance, stating that the current Secretary of the Board was recruited from a state-owned enterprise, emphasizing high compliance management standards [4]. - The company has undertaken substantial efforts in compliance and internal control, including appointing dedicated compliance personnel and implementing electronic process management [4]. - Future plans include enhancing compliance systems and culture, ensuring business operations and information disclosures are compliant and scientifically managed [4].

Group 1 - The core message emphasizes the potential of the "silver economy" in Guangyuan, highlighting the city's advantages in developing this sector and inviting entrepreneurs to invest [1][3] - Guangyuan City launched an "Investment Opportunity List for the Silver Economy" at the Sichuan International Elderly Care Industry Expo, featuring 23 projects with a total investment amount of 30.4 billion yuan [1] - The expo showcased Guangyuan's strengths in elderly care services, health tourism, rehabilitation aids, and traditional Chinese medicine for the elderly, indicating a solid foundation and vast investment prospects in the silver economy [3][6] Group 2 - The Guangyuan exhibition area at the expo was themed "Health and Wellness Paradise, Beautiful Guangyuan," featuring four main sections focused on elderly care services, health tourism, rehabilitation aids, and traditional Chinese medicine [3] - New products, such as tabletop games designed for elderly entertainment and rehabilitation, gained significant attention, reflecting a growing interest in innovative solutions for elderly care [6]

（原标题：和讯投顾冯珂：跌破万亿成交量！明天方向在这里！） 此外，今天连板票从昨天的9家猛增到21家，说明情绪资金抱团的趋势依然强劲。预计明天大盘震荡区 间在3355点到3330点之间，成交量有望突破万亿。如果明天继续跌破万亿，那反而更好，因为从去年9 月24日行情以来，大盘从未连续三天跌破万亿，所以主力一定会全力护盘，不仅仅是银行、证券护盘， 而是会出现普涨格局，让坚守的投资者都能迎来一波回血行情。 今天大盘创下本月最低成交量的同时，涨停家数达到95家，创下4天来的新高。这说明了两点：第一， 地量见地价，市场情绪已经到了冰点，所谓物极必反，市场随时可能出现反转。第二，资金抱团现象越 来越明显，虽然散户情绪不佳，但主力情绪高涨，很多高标股出现了资金接力的现象。这说明主力已经 提前入场，跟上主力节奏，就能逆势获利。 明天大盘的方向在哪里呢？今天农药兽药板块掀起涨停潮，带动了其他化工细分板块大涨。盘后消息显 示，一家农药公司发生事故，这或许会进一步推动化工板块的表现。每年4、5、6月份，化工板块都会 走出不少穿越牛股，所以明天化工板块有望继续掀起涨停潮。 医药板块也有两大利好：一是5月30日至6月3日，2025年 ...

Core Viewpoint - The company is changing the purpose of its 2024 share repurchase plan to reduce registered capital by canceling 6,620,630 shares, reflecting its commitment to shareholder value and social responsibility [1][2]. Group 1: Share Repurchase and Capital Management - The company has repurchased a total of 6.6206 million shares, accounting for 0.60% of its total share capital, with a cumulative repurchase amount of 98.0558 million yuan [2]. - The share repurchase plan aims to enhance shareholder rights and is expected to increase the per-share value by reducing the total share capital from 1.106 billion shares to 1.061 billion shares [2]. Group 2: Social Responsibility and Community Engagement - The company has paid nearly 32 billion yuan in taxes since its establishment, contributing significantly to local economic development and public welfare [3]. - In 2024, the company donated 10 million yuan worth of medical supplies to Ganzi Prefecture and 163 million yuan in medical resources to 148 counties in Tibet, improving grassroots medical conditions [3]. Group 3: Industry Position and Product Development - The company has established a diversified product system centered on traditional Chinese medicine, with significant sales in the cardiovascular sector, achieving a total revenue of 5.830 billion yuan in 2024 from key products [4]. - The company is focusing on innovative research and development, integrating traditional Chinese medicine with modern pharmaceutical practices, and advancing multiple projects in biopharmaceuticals and vaccines [5]. Group 4: Strategic Vision and Market Leadership - The company aims to build a strong competitive edge in the pharmaceutical industry, aspiring to become "China's Johnson & Johnson" and "the world's Buchang" through continuous innovation and market expansion [6].

会上，公司举行了首批战略合作签约仪式，与7家来自医药、保健品等领域的战略合作伙伴现场签 约，公司的香港代理商代表发言表示看好寿仙谷未来的品牌价值与市场潜力。大会结束后，多家经销商 就合作细节与公司展开进一步洽谈。 寿仙谷表示，未来将继续秉承"传承千年灵芝文化，科技赋能健康产业"的理念，加强与各地经销商 的深度合作，不断提升公司的核心竞争力。公司董事长李明焱亦表达了"打造全球灵芝产业标杆"的宏伟 愿景。 中证报中证网讯（王珞）5月24日至25日，寿仙谷首届全国招商大会于公司总部所在的浙江武义县 举办。大会以"世界好灵芝·中国寿仙谷"为主题，吸引政企代表、行业专家及全国合作伙伴参会，聚焦 中医药现代化与大健康产业发展。 寿仙谷作为《中医药-灵芝》《中医药-铁皮石斛》ISO国际标准制定者，长期致力于灵芝、铁皮石 斛等珍稀药材的全产业链布局。会上，公司展示了其在灵芝育种、仿野生栽培及孢子粉去壁技术等领域 的科研成果。 寿仙谷是国内首个自主培育灵芝新品种"仙芝1号"的公司，参会者实地参观了公司位于武义的生产 基地与生物育种中心，了解从育种到生产的全流程品控体系。 大会期间，寿仙谷公布了未来十年的市场开拓计划，提出以"专 ...